[HTML][HTML] Hughes-Stovin syndrome (HSS): current status and future perspectives
S Sanduleanu, TLTA Jansen - Clinical Rheumatology, 2021 - Springer
In 1959, John Patterson Hughes and Peter George Ingle Stovin, two British physicians,
described two male patients presenting with an undefined systemic illness characterized by …
described two male patients presenting with an undefined systemic illness characterized by …
Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis
…, H GROEN, PM HOUTMAN, TIMLTA JANSEN… - The Journal of …, 2011 - jrheum.org
Objective. To investigate whether level of serum matrix metalloproteinase-3 (MMP-3) can serve
as a biomarker for monitoring and predicting response to etanercept treatment in patients …
as a biomarker for monitoring and predicting response to etanercept treatment in patients …
Effectiveness of tumor necrosis factor inhibitors in combination with various csDMARD in the treatment of rheumatoid arthritis: data from the DREAM registry
SHM Manders, W Kievit, TLTA Jansen… - The Journal of …, 2016 - jrheum.org
Objective. To analyze and compare the effectiveness and drug survival in patients with
rheumatoid arthritis, as measured by 28-joint Disease Activity Score (DAS28) and Health …
rheumatoid arthritis, as measured by 28-joint Disease Activity Score (DAS28) and Health …
[HTML][HTML] A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior …
…, JFL Weel, JPL Spoorenberg, TLTA Jansen - Clinical …, 2011 - Springer
Abstract Treatment with TNFα inhibitors increases risk of reactivating a latent tuberculosis\infection
(LTBI). Therefore screening, prior to therapy with TNFα inhibitors, has been …
(LTBI). Therefore screening, prior to therapy with TNFα inhibitors, has been …
Impaired vasodilator response to atrial natriuretic factor in IDDM
P Smits, FMRJ Hersbach, TLTA Jansen, T Thien… - Diabetes, 1993 - Am Diabetes Assoc
Diabetes mellitus has been associated with both elevated plasma concentrations of the
natriuretic and vasorelaxant hormone atrial natriuretic factor and with a reduced natriuretic …
natriuretic and vasorelaxant hormone atrial natriuretic factor and with a reduced natriuretic …
Hemodynamic effects of atrial natriuretic factor in young and elderly subjects
TLTA Jansen, AC Tan, P Smits, T de Boo… - Clinical …, 1990 - Wiley Online Library
Because levels of plasma atrial natriuretic factor (ANF) increase with advancing age, a
diminished hemodynamic responsiveness to ANF in the elderly has been hypothesized in the …
diminished hemodynamic responsiveness to ANF in the elderly has been hypothesized in the …
Parenteral gold preparations. Efficacy and safety of therapy after switching from aurothioglucose to aurothiomalate.
…, M Janssen, MWM Kruijsen, TLTA Jansen… - The Journal of …, 2005 - jrheum.org
OBJECTIVE: For reasons of insufficient quality of the raw material, aurothioglucose was
withdrawn from the Dutch market at the end of 2001. Aurothiomalate became available as an …
withdrawn from the Dutch market at the end of 2001. Aurothiomalate became available as an …
Effectiveness of switch to a second anti-TNF-α in primary nonresponders, secondary nonresponders and failure due to adverse events
…, CMA De Gendt, TLTA Jansen… - ACR/ARHP Annual …, 2007 - research.utwente.nl
Purpose: It is known from previous studies that switching to a second antiTNFα may be effective
after failure to the first. However, it is unclear whether switching is as effective for patients …
after failure to the first. However, it is unclear whether switching is as effective for patients …
A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection
…, LC Nijdam, EN van Roon, KLL Movig, LTA Tim… - … of pharmaceutical and …, 2007 - Elsevier
OBJECTIVES: Allopurinol is a uric acid lowering drug used in the treatment of gout and the
prevention of tumor lysis syndrome. Allopurinol and its active metabolite oxipurinol inhibit …
prevention of tumor lysis syndrome. Allopurinol and its active metabolite oxipurinol inhibit …
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs …
EN van Roon, PMLA van den Bemt, LTA Tim… - Clinical …, 2009 - Elsevier
Background: Clinically relevant drug-drug interactions (DDIs) must be recognized in a timely
manner and managed appropriately to prevent adverse drug reactions or therapeutic failure…
manner and managed appropriately to prevent adverse drug reactions or therapeutic failure…